Overview

This trial is active, not recruiting.

Condition bowel preparation before colonoscopy
Treatment picosulfate sodium, magnesium oxide, citric acid
Phase phase 3
Sponsor Universal Integrated Corp.
Start date October 2013
End date March 2014
Trial size 600 participants
Trial identifier NCT01984008, UIC-BKL-2013

Summary

The primary objective of this study is to demonstrate that investigation medication (Bowklean) is not less effective than the active comparator (Klean-Prep with Dulcolax), with regards to the overall quality of bowel preparation in subjects undergoing colonoscopy. An additional objective of this study is to collect subject's response to the acceptability and tolerability about bowel preparation and safety information.

After bowel preparation, independent evaluator who is blinded to subject's treatment will evaluate the overall colon cleansing based on Aronchick and Ottawa scale. A total of 600 eligible subjects scheduled to a colonoscopy will be randomly assigned with equal allocation to 1 of 2 treatment groups: "Bowklean" or "Klean-Prep" with Dulcolax. Each subject's participation is expected to be maximally 4 weeks in study duration (up to 3-week screening period followed by one week post colonoscopy).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking single blind (outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
colonoscopy picosulfate,MgO, citric acid, bowel preparation, powder
picosulfate sodium, magnesium oxide, citric acid
(Active Comparator)
colonoscopy polyethylene glycol,powder bisacodyl,tablet
picosulfate sodium, magnesium oxide, citric acid

Primary Outcomes

Measure
The percentage of subjects that achieve excellent or good cleansing (success rate) in the Aronchick Scale.
time frame: six months

Secondary Outcomes

Measure
Proportion of successes (excellent, good, or fair) by individual colon segment (ascending, transverse, descending), which are assessed with the Ottawa scale.
time frame: six months

Eligibility Criteria

Male or female participants from 20 years up to 80 years old.

Inclusion Criteria: - Subject is 20 and 80 years, inclusive. - Men or non-pregnant women who are scheduled for an elective colonoscopy. - Subjects should be willing, able to complete the entire procedure and to comply with study instructions. - Written informed consent obtained prior to study. Exclusion Criteria: - Acute surgical abdominal conditions (e.g. acute obstruction or perforation, etc.) - Active (acute/exacerbation of/severe/uncontrolled) Inflammatory Bowel Disease (IBD) - Colon disease (history of colonic cancer, toxic megacolon, toxic colitis, idiopathic pseudo- obstruction, hypomotility syndrome) - Gastrointestinal disorder (active ulcer, outlet obstruction, gastric retention, gastroparesis, ileus) - Any prior colorectal surgery in the past 3 months, excluding appendectomy, hemorrhoid surgery or prior endoscopic procedures - History of upper gastrointestinal surgery (gastric resection, gastric banding, gastric by-pass) - Severe chronic constipation - Ascites - Renal insufficiency ((serum creatinine > 1.5 times the upper limit of normal (ULN))creatinine clearance < 30 mL/min) - Uncontrolled angina and/or Myocardial Infarction (MI) within last 3 months before randomization, Congestive Heart Failure (CHF), or uncontrolled hypertension - Participation in an investigational study within 60 days prior to receiving study medication - Any clinically significant laboratory value at screening, including pre-existing electrolyte abnormality, based on clinical history that the Investigator feels may affect the study evaluation - Hypersensitivity to any ingredient in the study medication

Trial information was received from ClinicalTrials.gov and was last updated in May 2015.
Information provided to ClinicalTrials.gov by Universal Integrated Corp..